A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Spontaneous Urticaria

In brief

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

Key facts

Study ID
NCT05368285
Run by
Celldex Therapeutics
People needed
208
Starts
2022-05-19
Expected to finish
2024-12-20
Last updated by the study team
2025-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.